Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
1. A method for treating a folate receptor-alpha-positive ovarian cancer in a subject in need of treatment of said cancer, said method comprising administering to said subject a therapeutically effective amount of paclitaxel and a therapeutically effective amount of an antibody that specifically binds folate receptor-alpha, wherein said antibody is produced by cells deposited as American Type Culture Collection accession number PTA-7552.
2. The method of claim 1 wherein said antibody is capable of both eliciting an immune effector activity and internalizing within folate receptor-alpha-positive ovarian cancer cells.
3. The method of claim 2 wherein said immune effector activity is antibody-dependent cellular cytotoxicity.
4. The method of claim 1 wherein said antibody is humanized.
5. The method of claim 1 wherein said subject is human.
6. The method of claim 1 wherein said administering of said antibody comprises injecting or infusing said antibody.
7. The method of claim 1 further comprising administering to said subject a therapeutically effective amount of cisplatin.